Three public EMT/mesenchymal signatures generated independently from meta-analyses across cancer types (Table 2; Supplementary Data S5) were used to validate that the PRRX1 signature captures a subgroup with mesenchymal biology. The gene discussed is PRRX1; the disease is cancer.